FDA Reported Monday It Is Requiring Boxed Warning For CAR-T Cancer Therapies
Portfolio Pulse from Charles Gross
The FDA has called for a boxed warning on CAR-T cancer therapies due to risks of serious side effects. Companies affected include BMY, GILD, JNJ, LEGN, NVS, and TSVT, which produce these therapies.
January 23, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol Myers Squibb, a producer of CAR-T therapies, may face negative investor sentiment due to FDA's call for boxed warnings.
The FDA's demand for a boxed warning is likely to be viewed negatively by investors as it may affect the perception of safety and potentially impact the sales of BMY's CAR-T products.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Gilead Sciences, involved in CAR-T therapy, could see a short-term dip in stock price due to the FDA's warning requirement.
As a manufacturer of CAR-T therapies, Gilead Sciences is directly impacted by the FDA's warning, which could lead to increased scrutiny and hesitancy among prescribers and patients.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Johnson & Johnson, a company with stakes in CAR-T therapy, may experience a negative impact on its stock due to the FDA's warning announcement.
Johnson & Johnson's involvement in CAR-T therapy means the FDA's decision could lead to adverse effects on the company's stock as it may influence market confidence and sales.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Legend Biotech, a CAR-T therapy producer, could face stock pressure following the FDA's call for a boxed warning on these treatments.
Legend Biotech's CAR-T products could be perceived as riskier due to the FDA's warning, potentially affecting investor sentiment and sales.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Novartis, a key player in CAR-T therapy, may see a short-term negative impact on its shares due to the FDA's warning requirement.
The FDA's boxed warning could dampen the appeal of Novartis' CAR-T therapies, potentially leading to a decrease in demand and investor concern.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
2seventy bio, with its focus on CAR-T therapies, could experience stock volatility following the FDA's demand for a boxed warning.
As 2seventy bio specializes in CAR-T therapies, the FDA's requirement for a boxed warning could negatively influence investor confidence and the company's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80